Comparing the current results to its competitors, Tenax Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.06 %, recorded in the same quarter.
Tenax Therapeutics Inc , slower than the average decrease reported by the company's competitors of -56.22 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -56.22 %
Tenax Therapeutics Inc 's Comment on Competition and Industry Peers
The company holds a patent for the use of TNX-101/102/103 (levosimendan) to treat pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), a condition for which no approved therapies currently exist. Success in this area depends on changing established treatment paradigms. Competitive factors include efficacy, safety, cost-effectiveness, hospital formulary approval, marketing exclusivity, and distribution. While levosimendan's mechanism is novel, competition may arise from low-cost generic products with similar therapeutic effects. Named competitors include AstraZeneca, Tectonic, and Merck. The pharmaceutical industry is highly competitive with rapid technological advancements, and developments by competitors, regulatory approvals, or superior marketing efforts could impact the commercial potential and financial results of the company's cardiovascular and pulmonary product candidates. Numerous pharmaceutical, biotechnology companies, and academic groups worldwide are engaged in related research and development.
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Pulmonx Corporation is a medical device company that specializes in the development and commercialization of minimally-invasive treatments for patients with severe emphysema. Their business model revolves around providing advanced solutions to physicians and healthcare facilities to improve patient outcomes and quality of life. The company focuses on developing and marketing innovative technologies, such as the Zephyr Valve System, which aim to address the unmet needs of patients suffering from severe emphysema.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Sources:
Tenax Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tenax Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
